Literature DB >> 21344350

Intrahepatic cholangiocarcinoma: new insights in pathology.

Christine Sempoux1, Ghalib Jibara, Stephen C Ward, Cathy Fan, Lihui Qin, Sasan Roayaie, M Isabel Fiel, Myron Schwartz, Swan N Thung.   

Abstract

Cholangiocarcinomas are malignant tumors that derive from cholangiocytes of small intrahepatic bile ducts or bile ductules (intrahepatic cholangiocarcinoma; ICC), or of large hilar or extrahepatic bile ducts (extrahepatic cholangiocarcinoma; ECC). ICC and ECC differ in morphology, pathogenesis, risk factors, treatment, and prognosis. This review focuses on ICC, which is rising in incidence with the emergence of hepatitis C virus (HCV) infection as a risk factor. The authors examined 73 ICC, which were resected at The Mount Sinai Medical Center in New York City, and reviewed the literature. The tumors were categorized into classical and nonclassical ICCs based on histopathology. Classical ICCs (54.8%) were characterized by a tubular, glandular, or nested pattern of growth, were significantly associated with tumor size of more than 5 cm and the absence of underlying liver disease and/or advanced fibrosis. Nonclassical ICCs (45.2%) consisted of tumors with trabecular architecture, tumors that exhibited features of extrahepatic carcinomas, and carcinomas considered to be derived from hepatic progenitor cells, i.e., combined hepatocellular/cholangiocarcinomas and cholangiolocellular carcinomas (ductular type of ICC). They were smaller and often arose in chronic liver disease, mostly HCV infection, and/or with significant fibrosis. The role of immunohistochemistry in the diagnosis of ICC and the importance of the new American Joint Committee on Cancer Staging System for ICC are also discussed. © Thieme Medical Publishers.

Entities:  

Mesh:

Year:  2011        PMID: 21344350     DOI: 10.1055/s-0031-1272839

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  65 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

Review 2.  Pathology of intrahepatic cholangiocarcinoma.

Authors:  Sandrine Vijgen; Benoit Terris; Laura Rubbia-Brandt
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

3.  Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study.

Authors:  Xianwu Luo; Lei Yuan; Yi Wang; Ruiliang Ge; Yanfu Sun; Gongtian Wei
Journal:  J Gastrointest Surg       Date:  2014-01-07       Impact factor: 3.452

Review 4.  Zebrafish models of human liver development and disease.

Authors:  Benjamin J Wilkins; Michael Pack
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

5.  A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management.

Authors:  Michael Postow; Manish A Shah; Maeve Lowery; Ali Shamseddine; Aghiad El-Kutoubi; Ashwaq Al Olayan; Mohamed Naghy; Celina Ang; Sally Tamraz; Abdul-Rahman Jazieh; Eileen M O'Reilly; David P Kelsen; Ghassan K Abou-Alfa
Journal:  J Gastrointest Cancer       Date:  2012-06

6.  Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma.

Authors:  Sen Guo; Hong-da Liu; Yan-Feng Liu; Lei Liu; Qiang Sun; Xi-Jun Cui
Journal:  Tumour Biol       Date:  2014-09-28

7.  New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Authors:  Jeffrey S Ross; Kai Wang; Laurie Gay; Rami Al-Rohil; Janne V Rand; David M Jones; Hwa J Lee; Christine E Sheehan; Geoff A Otto; Gary Palmer; Roman Yelensky; Doron Lipson; Deborah Morosini; Matthew Hawryluk; Daniel V T Catenacci; Vincent A Miller; Chaitanya Churi; Siraj Ali; Philip J Stephens
Journal:  Oncologist       Date:  2014-02-21

8.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

9.  Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma.

Authors:  Angela Y Jia; Jian-Xiong Wu; Yu-Ting Zhao; Ye-Xiong Li; Zhi Wang; Wei-Qi Rong; Li-Ming Wang; Jing Jin; Shu-Lian Wang; Yong-Wen Song; Yue-Ping Liu; Hua Ren; Hui Fang; Wen-Qing Wang; Xin-Fan Liu; Zi-Hao Yu; Wei-Hu Wang
Journal:  J Gastrointest Oncol       Date:  2015-04

Review 10.  Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications.

Authors:  Guergana G Panayotova; Flavio Paterno; James V Guarrera; Keri E Lunsford
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.